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arginase-1 activity in endometrial carcinomas compared 
with normal endometria, which was not the case for uterine 
sarcomas. Finally, we could demonstrate MDSC infiltra-
tion in fresh tumor suspensions from uterine tumors. these 
results indicate that the PD-1/PD-l1 interaction and B7-H4 
could be possible targets for immune intervention in uter-
ine cancer patients as well as mediation of MDSC function. 
these observations are another step toward the implemen-
tation of inhibitors of immunosuppression in the treatment 
of uterine cancer patients.
Keywords Immunosuppression · Uterine cancer · 
Immune checkpoints · IDO · galectins · Myeloid-derived 
suppressor cells
Abbreviations
eMCar  endometrial carcinoma
IDO  Indoleamine 2,3-dioxygenase
MDSC  Myeloid-derived suppressor cell
PD-(l)  Programmed death (ligand)
US  Uterine sarcoma
Introduction
Currently used immunotherapeutic regimens often result in 
immunological responses, such as antigen-specific t cell 
responses, but are all too often not accompanied by a cor-
relating clinical response. One of the reasons for the lack of 
consistent clinical responses is thought to be attributable to 
immune escape exerted by the tumor. Various mechanisms 
of immune evasion by tumors have been described, but 
the picture in uterine tumors is still enigmatic. By increas-
ing our knowledge on the involvement of these immune 
escape pathways in uterine tumors, we aim to identify new 
Abstract the major hurdle for cancer vaccines to be 
effective is posed by tumor immune evasion. Several com-
mon immune mechanisms and mediators are exploited 
by tumors to avoid immune destruction. In an attempt to 
shed more light on the immunosuppressive environment in 
uterine tumors, we analyzed the presence of PD-l1, PD-
l2, B7-H4, indoleamine 2,3-dioxygenase (IDO), galec-
tin-1, galectin-3, arginase-1 activity and myeloid-derived 
suppressor cell (MDSC) infiltration. IDO, PD-l1, PD-l2 
and B7-H4 were analyzed by immunohistochemistry. PD-
l2 was mostly expressed at low levels in these tumors. We 
found high IDO expression in 21 % of endometrial carci-
noma samples and in 14 % of uterine sarcoma samples. 
For PD-l1 and B7-H4, we found high expression in 92 and 
90 % of endometrial cancers, respectively, and in 100 and 
92 % of the sarcomas. galectin-1 and 3 were analyzed in 
tissue lysates by elISa, but we did not find an increase in 
both molecules in tumor lysates compared with benign tis-
sues. We detected expression of galectin-3 by fibroblasts, 
immune cells and tumor cells in single-cell tumor suspen-
sions. In addition, we noted a highly significant increase in 
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treatment options for this cancer type for which not much 
progress has been made in recent years.
One of the possible immune escape mechanisms are the 
so-called immune checkpoints. Immune checkpoints, some 
of which are briefly outlined below, comprise an array of 
pathways which the immune system occupies to maintain 
self-tolerance. Besides their natural function in the pre-
vention of among others autoimmunity, these molecules 
also play an important role in antitumor immunity, more 
specifically in the prevention/blockage thereof. the two 
checkpoints most focused on are Ctla-4 and PD-1. Sev-
eral inhibitors of these molecules are currently in clinical 
development and being analyzed in both the preclinical set-
ting as well as in clinical trials, with the aim of improving 
treatment outcome and survival in cancer patients [1–4].
PD-l1 and PD-l2, both members of the B7-CD28 fam-
ily, are ligands for the death receptor programmed death 
receptor 1 (PD-1), which play an important role in the cen-
tral t cell tolerance during t cell development [5]. PD-l1 is 
expressed in a variety of tissues, such as placenta, heart and 
spleen cells as well as islets and leukocytes [5, 6]. In tumors, 
PD-l1 expression has been abundantly detected and is often 
associated with a poor prognosis [7–9]. the expression pat-
tern of PD-l2 on the other hand is much more restricted. 
It is expressed mainly on dendritic cells and macrophages 
[6], but expression can be induced on several other immune 
and non-immune cells depending on environmental stim-
uli [10]. PD-l2 expression was shown in different tumor 
types, although mostly in a minority of patients [11–13]. 
PD-1/PD-l1 interactions have been shown to inhibit anti-
gen-experienced t cells in the periphery, thereby protecting 
normal tissues from immune destruction [3]. PD-l2 on the 
other hand is regulated by th2 cytokines and may itself pos-
sibly be involved in the modulation of th2 responses [10].
B7-H4 mrna is abundantly detected in human somatic 
tissues, but protein expression on tissues is limited [14]. On 
the contrary, B7-H4 protein expression has been found in 
many different types of human tumors [14], and soluble 
B7-H4 can be detected in the serum of cancer patients [15, 
16]. B7-H4 has been shown to play a role in the inhibition 
of activation, proliferation and clonal expansion of both 
CD4+ and CD8+ t cells [14, 17].
Indoleamine 2,3-dioxygenase (IDO) is an intracellu-
lar enzyme mediating the rate-limiting step of tryptophan 
catabolism along the kynurenine pathway. IDO medi-
ates “metabolic immune regulation” by depriving t cells 
of tryptophan and by the production of toxic metabolites, 
both leading to inhibition of t cell proliferation and induc-
tion of t cell death. Furthermore, IDO can convert naïve t 
cells into regulatory t cells (treg) and enhances their activ-
ity [18]. IDO expression has been observed in a variety of 
cancers, and high IDO expression is associated with dismal 
prognosis [19].
another family with important immunoregulatory func-
tions is the galectin family. the current manuscript is 
focused on galectin-1 and galectin-3. galectin-1 expression 
by tumors is associated with poor prognosis and the for-
mation of metastasis through modulation of among others 
cell migration, adhesion and angiogenesis [20]. Besides its 
direct effects on tumor progression, galectin-1 also plays a 
role in tumor immune regulation by creating a bias toward 
a th2 profile and activation of tolerogenic DC and Il-10 
producing regulatory (tr1) cells. galectin-3 is involved 
in the differentiation and proliferation of several immune 
cells. It activates both lymphoid and myeloid cells, such as 
t cells, mast cells, monocytes and neutrophils [20]. galec-
tin-3 is also a negative regulator of immune cell function 
by controlling the anergic state of t cells [21]. galectin-3 
is capable of forming lattices with the t cell receptor com-
plex, thereby intervening with t cell receptor signaling and 
subsequent t cell activation [20].
Other key players in tumor immune suppression are cer-
tain types of immune cells, such as treg or myeloid-derived 
suppressor cells (MDSC). the latter are a heterogeneous 
population of immature myeloid cells with monocytic and/
or granulocytic features. MDSC exert their suppressive 
function by depleting l-arginine from the tumor micro-
environment via the production of arginase-1. the deple-
tion of l-arginine subsequently causes a down-regulation 
of the ζ-chain of the t cell receptor, [22, 23] as well as 
cell cycle arrest of t cells [24]. Furthermore, MDSC pro-
duce reactive oxygen species (rOS) and nitric oxide (nO) 
radicals, which also capable of suppressing t cell function 
[25]. MDSC have been implicated in various tumors and 
are correlated with poor prognosis [26, 27]. MDSC levels 
might serve as a predictive marker for clinical outcome of 
oncologic treatment [25, 28].
We have used an immunohistochemical approach to 
validate the presence of IDO in uterine tumors, as well as 
to investigate the presence of PD-l1/PD-l2, to our knowl-
edge not described in this type of tumor before, and B7-H4.
In addition, we have analyzed the expression of galec-
tin-1 and 3 in uterine tissue samples by elISa and con-
firmed galectin-3 expression on cellular subtypes in uterine 
tumor specimens by flow cytometry. the activity of argi-
nase-1 in uterine tissue samples was determined, and we 
further provided evidence of MDSC infiltration in uterine 
tumor specimens by multi-parametric flow cytometry.
Materials and methods
Biopsy material
all biopsies were collected at the University Hospital 
leuven, campus gasthuisberg, from patients undergoing 
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surgery at the Department of gynecologic Oncology. When 
possible, multiple blocks were used from the same tumor 
to a maximum of three tumor blocks per tumor. the latter 
was done in order to obtain an idea of expression across the 
entire tumor. Samples of normal endometrium or myome-
trium were collected from patients undergoing surgery for 
benign afflictions.
the collection of all human samples was approved by 
the Institutional review Board of the University Hospitals 
leuven and written informed consent was obtained from 
all patients.
Immunohistochemical staining
For all stainings, 4.0 μm formalin- or Bouin-fixed paraffin-
embedded tissue slides were used. all slides were depar-
affinized and rehydrated prior to staining. the general steps 
for each of the staining procedures are similar comprising 
the consecutive steps of endogenous alkaline phosphatase 
or peroxidase inhibition using 0.2 n HCl or 0.5 % H2O2 
in methanol, respectively, followed by heat-induced epitope 
retrieval (HIer), blocking of slides to prevent aspecific 
antibody binding, and application of the appropriate anti-
bodies and visualization methods. the specifications of 
these steps for each of the staining procedures are summa-
rized in table 1.
Scoring system
Before scoring the tissue slides, tumor tissue was iden-
tified using a conventionally stained He tissue slide of 
the same tumor. all slides were scored with a scoring 
system, partially adopted from Ino et al. [29]. all slides 
were given two separate scores. One for the percentage 
of total tumor cells showing expression, divided in three 
different categories: 1–25; 25–50; >50 %. each of these 
parameters was subsequently given a score of 1, 2 and 3, 
respectively. the second score was given according to the 
intensity of the expression: 1 (weak), 2 (moderate) and 3 
(strong). Depending on the sum of the two scores, a final 
value was given. a sum of 0–1 = final score 0; 2–3 = 1; 
4–5 = 2 and 6 = 3. Based on these scores, a discrimina-
tion between biopsies with high and low expression lev-
els was made, adopted from De Jong et al. [30]. Biopsies 
with a total score of 0–1 are classified as low score (lo), 
and biopsies with a total score of 2–3 are classified as 
high score (hi). the intensity scores which match the vis-
ual aspect of the staining were determined for each mol-
ecule separately.
tumor lysate preparation
150–200 mg of snap-frozen tissue samples were lysed by 
mechanical friction using magnetic stones after adding 
lysis buffer consisting of 250 mM tris HCl, 750 mM naCl, 
0.5 % SDS, 2.5 % deoxycholic acid, 5 % Igepal and 0.01 % 
protease inhibitor cocktail (Mammalian Cell lysis Kit; 
Sigma-aldrich). after incubating the minced tissue mate-
rial for 30 min at 4 °C, the lysed material was purified from 
debris through centrifugation. Protein content was deter-
mined using the Pierce BCa Protein assay (thermo Scien-
tific) according to manufacturer’s instructions.
Table 1  experimental conditions of IHC procedures
a
 HIER heat-induced epitope retrieval
b
 APAAP alkaline phosphatase–anti-alkaline phosphatase
c
 HRP horse radish peroxidase
d
 NBT nitro blue tetrazolium
e
 DAB 3,3′-diaminobenzidine
target IDO PD-l1 PD-l2 B7-H4
HIERa
Buffer tris–HCl + 1 mM eDta tris–HCl + 1 mM eDta tris–HCl + 1 mM eDta Citrate
time 2 h 1.5 h 2 h 1 h
temperature 90 °C 90 °C 90 °C 90 °C
Primary antibody
antibody Ms anti Hu IDO (Chemicon) rb anti Hu PD-l1 (abcam) Ms anti Hu PD-l2 (r&D 
Systems)
rb anti Hu B7-H4 (epitom-
ics)
Final concentration 2 μg/ml ready to use 0.8 μg/ml 1/600 dilution
Secondary antibody go anti Ms Igg-Po +  
aPaaPb complex
envision system anti rb- 
HrPc
envision system anti Ms- 
HrP
envision system anti rb-HrP
Visualization nBtd DaBe DaB DaB
Counterstaining hematoxylin hematoxylin hematoxylin hematoxylin
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galectin-1 elISa
ninety-six-well plates were coated overnight with goat 
anti-human galectin-1 (r&D Systems, 2 μg/ml in PBS). 
after blocking the wells with 1 % BSa in PBS for 1 h at 
room temperature (rt), standards (recombinant galectin-1; 
range 25–0.39 ng/ml) and samples were added for 2 h at 
rt. analyses were performed on tumor lysates at a concen-
tration of 5 mg/ml. Detection was done using a combina-
tion of goat anti-human Igg (r&D systems, 200 ng/ml) 
and HrP-conjugated streptavidin, followed by incubation 
with tMB substrate. the reaction was stopped using 2 M 
H2SO4, and OD was measured at 450 nm, with 540 nm as 
reference wavelength.
galectin-3 elISa
galectin-3 detection was performed using a commercially 
available elISa (r&D Systems) with minor modifications. 
For coating, mouse anti-human galectin-3 (2 μg/ml) was 
used. the galectin-3 standard was used within the range of 
4,000–62.5 pg/ml. Detection was performed using mouse 
anti-human Igg in combination with HrP-conjugated strepta-
vidin. all other steps are identical to galectin-1 detection.
arginase-1 activity assay
Measurement of arginase-1 activity, through determination 
of the urea content in tumor lysates (at a concentration of 
5 mg/ml), was performed using the QuantiChrom™ argi-
nase assay Kit (Bioassay Systems) following the manufac-
turer’s protocol.
Preparation of single-cell suspensions from tumor biopsies
Single-cell suspensions of fresh tumor biopsies were pre-
pared by a combination of mechanical dissociation and 
enzymatic digestion using the Human tumor Dissocia-
tion Kit (Miltenyi Biotec) and the gentleMaCS dissocia-
tor (Miltenyi Biotec). Briefly, the protocol for soft tumors 
was followed, according to manufacturer’s instructions. 
the cell suspensions were purified on a 40 μm cell strainer 
and counted with türck’s solution. Single-cell suspensions 
from tumor biopsies were either used fresh or after cryo-
preservation for subsequent flow cytometric analysis.
Flow cytometric analysis
Cell suspensions were first stained with a fixable viabil-
ity dye (Fixable Viability Dye eFluor 506, eBioscience) 
for discrimination of live and dead cells. after washing 
with PBS, Fc receptor blocking was performed by add-
ing a 10 % normal goat serum (Sigma-aldrich) solution 
in PBS/0.5 % BSa. For single-cell tumor suspensions, red 
blood cell lysis was performed after the membrane stain-
ing using 1× Pharmlyse (BD Pharmingen), according to 
manufacturer’s instructions.
galectin-3 expression by primary tumor cell lines was 
evaluated by staining with galectin-3-Pe (Biolegend) or the 
appropriate isotype control, either on the membrane or intra-
cellularly after fixation/permeabilization using the FoxP3 
Staining Buffer Set (eBioscience). acquisition was performed 
with a FaCS Canto II flow cytometer using BD FaCS DIVa 
software, and 3 × 104 cells were acquired per sample. Data 
analysis was done using BD FaCS DIVa software. Cells 
were gated on FSC/SSC characteristics and analyzed for the 
expression of membranous or intracellular galectin-3.
For the analysis of galectin-3 expression by different cell 
types, we used the following antibody cocktail: CD90-FItC 
(Biolegend), galectin-3-Pe (Biolegend), epCaM-PerCP-
Cy5.5 (Biolegend) and CD45-aPC-H7 (BD Pharmingen). 
Intracellular expression of galectin-3 was assessed after 
fixation/permeabilization with the FoxP3 Staining Buffer 
Set (eBioscience). acquisition was performed with a FaCS 
Canto II flow cytometer using BD FaCS DIVa software, 
and between 2.5 × 104 and 1 × 106 cells were acquired 
in the live gate per sample. Data analysis was done using 
BD FaCS DIVa software. Cells were gated as follows: 
first, dead cells were gated out using the viability dye, and 
cells were gated based on FSC/SSC characteristics. next, 
CD90+ fibroblasts, CD45+ immune cells and epCaM+ 
tumor cells (for eMCar), or CD45− CD90− tumor cells 
(for US) were gated, and each analyzed for the expression 
of membranous or intracellular galectin-3. appropriate iso-
type controls were included to set the gates for the positive 
and negative populations.
For enumeration of MDSC, the following antibody cock-
tail was used: CD45-FItC (Biolegend), CD11b-Pe (Biole-
gend), CD14-PerCP-Cy5.5 (BD Pharmingen), CD3-Pe-Cy7 
(Biolegend), CD19-Pe-Cy7 (Biolegend), CD56-Pe-Cy7 
(Biolegend), CD15-aPC (Biolegend), Hla-Dr-aPC-H7 
(BD Pharmingen) and CD33-V450 (BD Horizon). analysis 
of arginase-1 expression was done by replacing CD45-FItC 
with arginase-1-fluorescein (r&D Systems) in the above-
mentioned MDSC cocktail. For assessment of arginase-1 
expression, cells were first stained for membrane markers, 
subsequently fixed and permeabilized using the FoxP3 Stain-
ing Buffer Set (eBioscience) and stained with arginase-1-flu-
orescein (r&D Systems). acquisition was done as mentioned 
above for assessment of galectin-3 on tumor subpopulations. 
Data analysis was done using BD FaCS DIVa software. 
the following gating strategy was used for enumeration of 
MDSC: first, dead cells were gated out using the viability 
dye, and cells were gated based on FSC/SSC characteris-
tics, followed by CD45 positivity. next, a gate was defined 
for lineage-negative (CD3-, CD19- and CD56-negative), 
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Hla-Drlow/− cells. Within this population, CD11b+ CD14− 
granulocytic MDSC and CD11b+ CD14+ monocytic MDSC 
were specified. On both cell types, the expression of CD15 
and CD33 was documented. arginase-1 expression by MDSC 
was analyzed as follows: dead cells were gated out using the 
viability dye, and cells were gated based on FSC/SSC char-
acteristics. next, the lineage-negative (CD3-, CD19- and 
CD56-negative), Hla-Drlow/− cell population was identi-
fied. Within this population, CD11b+ CD14− granulocytic 
MDSC and CD11b+ CD14+ monocytic MDSC were defined, 
and the expression of arginase-1 on both subtypes was ana-
lyzed. Proper isotype controls were used to set the gates for 
the positive and negative populations.
Statistics
Statistical analyses were done using the graphPad Prism 
5.0 software. all scoring data were analyzed using the non-
parametric Kruskal–Wallis test, followed by the Dunn’s 
multiple comparison test. Differences in proportion were 
calculated using the Fischer exact test. Multiple group 
comparisons were performed using either anOVa or Stu-
dent’s t test. Comparison of survival curves was performed 
using the log-rank (Mantel–Cox) test.
Results
IDO expression in uterine tumors
Patient characteristics of the IHC analysis of IDO, PD-
l1, PD-l2 and B7-H4 are summarized in Supplementary 
table 1. IDO is present in 57 % of normal endometria 
(table 2). When looking at the carcinomatous tumors, we 
found IDO to be present in only 36 % of the primary endo-
metrial cancers (eMCar). It is slightly, yet not signifi-
cantly, increased in the metastatic locations (44 %). Sixty 
percent of the currently analyzed recurrent eMCar sam-
ples showed IDO expression. the enzyme is present in only 
a minority of sarcoma samples, and the expression level is 
generally low in this tumor type (Fig. 1). In comparison 
with normal endometrium, both the percentage of positive 
tumors (p < 0.01) and the expression level are significantly 
lower in primary US (p < 0.01) and recurrent US (p < 0.05). 
IDO is present in a significantly lower proportion of meta-
static US lesions compared with normal endometrium 
(p < 0.05) and at a lower expression level (p < 0.05). the 
expression pattern of IDO was mainly cytoplasmic. In the 
eMCar biopsies, in some tumors, clear apical expression 
could be detected (Supplemental Fig. 1). In addition, IDO 
expressing infiltrating cells could be detected in the tumor 
periphery of some of the analyzed tumors, both carcinoma 
and sarcoma. 
twenty-one percent of primary eMCar samples were 
IDOhi, while for US, 14 % of primary tumors were IDOhi, 
indicating that IDO blockade could be a useful strategy in a 
minority of patients.
PD-l1 expression
Overall, PD-l1 is expressed in the vast majority of the 
currently tested samples (Fig. 2a). the expression pattern 
for PD-l1 was cytoplasmic in all of the analyzed biop-
sies (Supplemental figure 2). We found PD-l1 expression 
Table 2  Immune checkpoint and IDO expression in different sample types
a
 nl EM normal endometrium
b
 pr EMCAR primary endometrial carcinoma
c
 rec EMCAR recurrent endometrial carcinom
d
 meta EMCAR metastatic endometrial carcinoma
e
 pr US primary uterine sarcoma
f
 rec US recurrent uterine sarcoma
g
 meta US metastatic uterine sarcom
Sample IDO PD-l1 PD-l2 B7-H4
N % positive N % positive N % positive N % positive
nl eMa 14 57 16 81 15 47 15 100
pr eMCarb 28 36 29 83 30 40 30 100
rec eMCarc 11 60 9 67 5 60 11 100
meta eMCard 9 44 9 100 9 44 10 90
pr USe 22 14 21 100 19 32 26 100
rec USf 13 15 11 100 4 0 13 92
meta USg 13 15 10 100 11 27 13 100
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in 81 % of normal endometria. In 4/16 of the analyzed 
normal endometria, PD-l1+ cells infiltrating the endo-
metrium were seen. PD-l1 expression in tumors was 
found in 70–80 % of the eMCar samples and in all of 
the US samples. the number of analyzed samples and 
the corresponding percentages for each group are sum-
marized in table 2. When analyzing the expression level, 
we found an up-regulation in primary sarcomas in com-
parison with normal endometrium (p < 0.01). Overall, the 
expression level of PD-l1 was moderate to high. Of the 
patients with primary eMCar, 72 % showed high PD-l1 
expression, and for US, all patients were PD-l1hi, which 
shows that interference with the PD-1/PD-l1 axis could 
represent a promising new treatment option for uterine 
cancer patients. For eMCar, we noticed a trend toward 
improved survival for patients with PD-l1hi tumors 
(p = 0.084, data not shown).
PD-l2 expression
the expression of PD-l2 was different from the expression 
of PD-l1 (table 2). We found that 47 % of normal endo-
metria expressed PD-l2. In eMCar in general, the per-
centage of positive tumor samples varied from 40 to 70 %, 
while in the US group, this ranged from 0 to 32 % positive 
tumors. In general, the intensity scores for all the biopsies 
were low to moderate, and we did not find any differences 
in expression levels between any of the analyzed groups 
(Fig. 2b). next to intracytoplasmic expression in tumor 
cells, we found the presence of PD-l2+ cells, possibly 
reflecting immune cell infiltrates in 10/30 (33 %) analyzed 
primary eMCar biopsies as well as in 2/9 (22 %) of the 
included metastatic eMCar lesions. the infiltrating cells 
were found intratumorally, in the tumoral stroma and in the 
tumor periphery (Supplemental figure 3).
Overall, in primary tumors, 30 % of eMCar patients 
and 16 % of US patients showed high PD-l2 expression, 
thereby demonstrating the potential of PD-l2 blockade in a 
limited proportion of uterine cancer patients.
B7-H4 expression
B7-H4 is expressed in the vast majority of the currently 
analyzed biopsies (table 2). In-depth analysis of the 
expression levels revealed no differences between any of 
the groups (Fig. 2c). B7-H4 is expressed exclusively in 
the cytoplasm (Supplemental figure 4). Due to the visual 
aspects of the staining, discrimination of infiltrating cells 
was not possible.
the high expression levels of B7-H4 in both primary 
eMCar (90 % of samples) and primary US (92 % of sam-
ples) make this an attractive candidate for uterine cancer 
therapy.
galectin-1 and galectin-3 levels
galectin-1 and 3 presence in tumor tissue lysates was 
tested by elISa in 29 eMCar patients, 30 US patients, 
21 normal/benign endometria and 18 normal myometria. 
the characteristics of the patients used for this study are 
summarized in Supplementary table 2. We found that 
galectin-1 is present in all of the different analyzed tissues, 
without significant differences between the entire sample 
groups (Fig. 3a). When subdividing the US group, a sig-
nificant galectin-1 up-regulation was found in leiomyosar-
comas compared with myometrium (p < 0.01), carcinosar-
comas (p < 0.05) and other US subtypes (p < 0.05). For 
galectin-3, we found a significantly higher intratumoral 
level in eMCar samples compared with US samples 
(p < 0.05), shown in Fig. 3b.
For galectin-3, it was determined whether it is expressed 
on eMCar and US cell lines (primary cell lines gener-
ated in our lab, kind gift from Dr. Coenegrachts) by flow 
cytometric analysis, and limited galectin-3 expression 
Fig. 1  IDO expression levels 
in uterine tumors. a Percentage 
of tumors/normal endometrium 
positive for IDO. b Overall 
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was detected on the plasma membrane, but nearly com-
plete intracellular expression was found in these cell lines 
(Supplementary table 3). Further assessment of its expres-
sion levels on fibroblasts, immune cells and tumor cells in 
single-cell suspensions from fresh tumor biopsies (tumor 
characteristics shown in Supplementary table 4) firstly 
showed considerable variation in the cellular composi-
tion of the single-cell tumor suspensions: 1.24–16.16 % 
fibroblasts, 15.19–75.07 % immune cells and 6.73–80.21 % 
tumor cells (data not shown). When gating on these differ-
ent cell populations, a slightly higher percentage of mem-
branous galectin-3 positivity on tumor cells versus fibro-
blasts and immune cells was found, although this did not 
reach statistical significance, shown in Fig. 3c. With regard 
to intracellular galectin-3 expression, the majority of fibro-
blasts, immune cells and tumor cells expressed galectin-3. 
Fig. 2  Immune checkpoints 
in uterine cancer. Left panels 
percentage of positive tumors/
normal endometrium. Right 
panels Overall expression levels 
between groups. a IHC analysis 
of PD-l1 expression. b IHC 
analysis of PD-l2 expression. c 
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Intracellular galectin-3 expression was significantly higher 
in tumor cells versus fibroblasts (p < 0.05).
arginase-1 activity and MDSC infiltration
arginase-1 activity was measured in tissue lysates of 25 
normal endometria, 39 eMCar, 27 US and 18 normal 
myometria. Clinical parameters of all patient samples are 
depicted in Supplementary table 5. activity was signifi-
cantly up-regulated in eMCar samples compared with 
normal endometria (p < 0.0001). no difference in activity 
was found between normal myometria and US samples 
(Fig. 4a). these data suggested a possible implication of 
MDSC in endometrial carcinoma and inspired us to explore 
whether MDSC infiltration can be found in eMCar and 
US tumors. therefore, single-cell suspensions from fresh 
tumor biopsies were prepared (tumor characteristics shown 
in Supplementary table 6), and flow cytometric analysis 
to detect MDSC and assess their arginase-1 expression 
was performed. MDSC infiltration was indeed detected in 
tumor specimens, and these cells were mainly of granu-
locytic phenotype (lin− Hla-Drlo/− CD11b+ CD14−; 
Fig. 3  galectin expression 
in patient plasma and uterine 
tissue samples. a galectin-1 
expression in uterine tissue. Left 
panel overall galectin-1 expres-
sion. Right panel galectin-1 
expression in myometrium 
versus sarcoma histological sub-
types. b galectin-3 expression 
in uterine tissue. c Flow cyto-
metric detection of galectin-3 
on different cell populations 
within single-cell tumor suspen-
sions. Left panel membranous 
galectin-3 expression. Right 
panel intracellular galectin-3 
expression
A Galectin-1 tumor lysate
B Galectin-3 tumor lysate
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Fig. 4b). tumors contained significantly more granulocytic 
compared with monocytic MDSC (p = 0.0124). However, 
both MDSC subtypes expressed similar arginase-1 levels 
(Fig. 4c). the majority of the granulocytic MDSC were 
CD15+, with approximately half of them co-expressing 
CD33. the monocytic MDSC were mainly CD15+ CD33+ 
(approximately 60 %), with an additional 24 % of CD15+ 
CD33− cells (data not shown).
Discussion
In the current research, we have evaluated the expression 
of PD-l1, PD-l2, B7-H4, IDO, galectin-1 and galectin-3 
in uterine tumors and documented the arginase-1 activity 
and MDSC infiltration in these tumors. to our knowledge, 
this is the first paper to describe the presence of PD-l1 and 
PD-l2 in endometrial cancer as such, and we are not aware 
that any of the currently described molecules have been 
described in uterine sarcoma so far, except for possibly 
IDO [31], galectin-1 [32] and galectin-3 [32–34].
Both PD-1 ligands have previously been implicated in 
different types of cancer, although more is known about 
PD-l1 expression in several types of tumors, such as mela-
noma, brain tumors, lung cancer, urothelial cancer and pan-
creatic cancer [7, 35–38]. In soft tissue sarcomas in general, 
one study found expression of PD-l1 in 65 % of cases [9]. 
to date, little information is available on the expression of 
both ligands in gynecological tumors in general. Our data 
on PD-l1 expression show that it is expressed in the vast 
majority of both normal endometrial samples and of endo-
metrial tumors, with no difference in proportion or expres-
sion level between any of the analyzed groups. In con-
trast to what we anticipated, we observed a trend toward 
improved overall survival in patients with PD-l1hi tumors. 
However, this phenomenon has previously been described 
in melanoma, merkel cell carcinoma and MMr-proficient 
colorectal carcinoma [39–41]. Up-regulation of PD-l1 
has been shown to be driven by IFnγ and CD8+ t cells. 
Hence, PD-l1 expression could be viewed as a result of an 
ongoing endogenous anti-tumor immune response and thus 
may represent a negative feedback loop dependent on an 
infiltrating immune response [42, 43].
PD-l2 has long been thought to be present only on 
dendritic cells and macrophages. However, more evidence 
is beginning to emerge of PD-l2 presence on somatic tis-
sues and in cancer as well. It has, for example, been shown 
to be present in cancer-associated fibroblasts (nazareth 
et al. [10]) as well as in esophageal [13] and hepatocellu-
lar carcinoma [11]. Most of the currently analyzed biop-
sies were negative for PD-l2, except in the recurrent car-
cinoma group. Similar to our results of low expression in 
Fig. 4  arginase-1 activity 
in uterine tissues and MDSC 
infiltration in uterine tumors. a 
arginase-1 activity in uterine 
tissues. b MDSC infiltration in 
uterine tumors. c arginase-1 
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the majority of tumors, a study in ovarian cancer has shown 
that the majority of the tumors are negative for PD-l2 [12]. 
Both ligands have also been investigated in cervical cancer 
[44], both being present in only a minority of the investi-
gated samples.
B7-H4 has been shown in different tumors, summarized 
by He et al. [14]. Quite some data are available on its pres-
ence in breast cancer and ovarian cancer. It has been shown 
to be present intracellularly in ovarian tumor cells and on 
tumor-associated macrophages (taM) in these tumors [45, 
46]. B7-H4 expression levels were correlated with patient 
outcome [45]. two studies report on B7-H4 expression 
in endometrial cancer [47, 48]. Both studies show B7-H4 
expression in normal endometrium, and B7-H4 staining 
was shown to increase from normal to malignant endome-
trial glands. Our results are somewhat contradictory since 
we found high B7-H4 levels in almost all of the analyzed 
tissue samples in both benign and malignant endometrial 
tissues as well as in US samples. this observation might 
be due to the use of different antibodies, staining protocols 
and/or scoring protocols.
the immune inhibitory enzyme IDO has also been 
shown to play an important role in cancer-induced immu-
nosuppression by depriving t cells of tryptophan and thus 
preventing their activation [49]. Uyttenhove et al. [31] 
described IDO in 25 different tumors. IDO has previously 
been detected in ovarian [31, 50] as well as endometrial 
tumors [29–31, 51, 52]. We have found high IDO expres-
sion in 21 % of primary endometrial tumors, which is in 
line with data reported by De Jong et al. (18,1 %), but 
lower than the results obtained by Ino et al. (46–49 %). 
We have also found an increased IDO expression level 
in recurrent eMCar compared with primary eMCar, 
pointing to increased immunosuppression in recurrent 
tumors. We found IDO expression only in a minority of 
US, in corroboration with Uyttenhove et al., who found 
IDO expression in 20 % of sarcomas. However, the exact 
subtype of sarcoma is not specified any further [31]. 
except for PD-l1, no correlation between high and low 
expression and patient overall survival was found (data not 
shown). However, the currently analyzed sample popula-
tion is too small to perform sound survival analyses. Based 
on the current data, no definitive conclusion can be made 
regarding patient survival. When analyzing the current 
sample population, no differences were found regarding 
FIgO stage, histological subtype or histological grade, 
except for a significantly lower expression level of IDO 
in grade 3 tumors compared with grade 1 (p < 0.05; data 
not shown). In addition, we could not find a difference in 
expression level between type I and type II eMCar for 
any of the analyzed mediators. We do, however, acknowl-
edge that the current sample sizes are too small to perform 
adequate statistical analyses regarding sub-parameters, 
which may bias or mask possible differences in expression 
levels.
galectin-1 and galectin-3 have both been described in 
tumors. galectin-1 and galectin-3 are both up-regulated 
in among others bladder carcinoma [53, 54], head and 
neck squamous cell carcinoma (HnSCC) [55] and ovar-
ian cancer [56, 57]. Several studies have been published 
on galectins in endometrial cancer, with contradictory 
results. galectin-1, but not galectin-3, has been shown to 
be increased in eMCar compared with normal endome-
trium [58]. Similarly, galectin-1 was found to be increased 
in endometrioid eMCar from well differentiated to 
undifferentiated carcinoma [59]. Contradictory to the data 
by Van den Brule et al. [58], Brustmann et al. [60] were 
able to show an increase in galectin-3 in eMCar samples 
compared with normal endometrium samples. However, 
ege et al. [61] reported decreased galectin-3 expression 
in eMCar samples compared with normal endometrium. 
We currently found no increased galectin-1 or galectin-3 
expression in tissue lysates of eMCar or US compared 
with normal/benign controls. However, galectin-1 levels 
in lysates of leiomyosarcomas were significantly higher 
compared with myometrium, carcinosarcomas and other 
histological subtypes of US. We further showed both mem-
branous and cytoplasmic expression of galectin-3 on sin-
gle-cell tumor suspensions from primary tumors and on 
uterine cancer cell lines. In cancer, there is often a change 
in intracellular localization of galectin-3. Brustmann et al. 
[60] found an increased nuclear expression in eMCar. 
Data of Mylonas et al. showed that it can be detected in 
both the cytoplasm and the nucleus [58], but exclusively, 
cytoplasmic expression was associated with increased 
myometrial invasion of eMCar [58]. In the current study, 
we used tissue lysates or membrane/intracellular flow cyto-
metric analysis, and consequently, no analysis on galectin 
location could be done to corroborate these data. Weis-
senbacher et al. [34] analyzed the expression of galectin-1 
and galectin-3 in uterine leiomyosarcoma. Contradictory to 
what we currently found in the total sarcoma population for 
galectin-1, they found no difference in galectin-1 or galec-
tin-3 expression when compared with normal myometrium. 
this discrepancy may in part be explained by the use of a 
semi-quantitative versus a quantitative analysis method in 
the current setting, which creates some difficulties for pre-
cise comparison of results.
Myeloid-derived suppressor cells have been shown to 
play an important role in cancer immunosuppression. de 
Boniface et al. [62] showed increased expression of argi-
nase-1 on MDSC in breast cancer patients, which corre-
lated with tumor grade. arginase-releasing MDSC exert-
ing detrimental effects on t cells are also increased in 
patient blood of renal cell carcinoma (rCC) patients [63, 
64]. We have currently analyzed the activity of arginase-1 
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as a surrogate for MDSC. We found increased arginase-1 
activity in eMCar lysates compared with normal endo-
metrium, indicating a possible involvement of MDSC in 
eMCar. Furthermore, we showed for the first time that 
both eMCar and US tumors contain MDSC infiltrates that 
express arginase-1.
In conclusion, we report the presence of the immune 
checkpoints PD-l1/PD-l2 and B7-H4 in uterine tumors as 
well as the presence of the immune inhibitory molecules 
IDO, arginase-1, galectin-1 and galectin-3 and the immu-
nosuppressive MDSC. the current data in conjunction with 
positive results of currently ongoing clinical trials and pre-
clinical studies with inhibitors for these molecules advocate 
for a possible future use in patients suffering from uterine 
tumors. In our opinion, IDO and PD-l2 are useful tar-
gets for immune inhibition in a minority of uterine cancer 
patients. Both PD-l1 and B7-H4 could represent targets 
in both tumor types, considering their high expression lev-
els. Finally, intervention with MDSC function offers a new 
treatment perspective in eMCar patients.
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